Target intelligence / Profile preview

Glycosaminoglycan (heparin) (GAG (heparin))

Target
GAG (heparin)
Molecular classification
Other (linear polysaccharide/complex carbohydrate), Glycan, Extracellular matrix component
01

Overview

Glycosaminoglycans (GAGs) are long, linear polysaccharides consisting of repeating disaccharide units, classified into types such as heparin, heparan sulfate, chondroitin sulfate, and others. Heparin is a highly sulfated GAG best known for its potent anticoagulant properties, achieved by potentiating antithrombin III and thereby inactivating thrombin and other clotting factors. Beyond blood coagulation, heparin and related GAGs are important modulators of cell signaling, extracellular matrix structure, and inflammation. Though heparin (as a drug) is therapeutically targeted, glycosaminoglycans as a class are molecular structures, not classical "targets" (like receptors or enzymes), and the term “glycosaminoglycans / heparin” is imprecise as a therapeutic target. GAGs can be exploited pharmacologically (e.g., exogenous heparin for anticoagulation), but are generally substrates and modulators, not drug targets themselves.

Other names
HeparinHeparan sulfate (closely related, but not identical)GAG (for the superclass)HSGAG (heparin/heparan sulfate glycosaminoglycan)Glycosaminoglycan
02

Mechanism of action

Potentiates antithrombin III (ATIII), leading to inhibition of thrombin (factor IIa) and factor Xa, providing anticoagulant effect. Binds numerous extracellular proteins (growth factors, cytokines) to modulate signaling

03

Biological functions

Anticoagulation (heparin specifically)Modulation of cytokine and growth factor activityStructural support in extracellular matrixRegulation of cell adhesion, proliferation, and differentiationMediation of interactions between cells and proteinsRegulation of enzyme activity (e.g., inhibition of proteases)Mediation of inflammation and wound healing
04

Disease associations

Cardiovascular disease (heparin as an anticoagulant in thrombosis, embolism)InflammationInfection (roles in viral entry and spread, e.g., HIV, HSV)Cancer (altered GAG expression linked to tumor progression)Other (as broad group: implicated in connective tissue disorders, inherited metabolic diseases)
05

Safety considerations

Bleeding/hemorrhage (due to anticoagulant action)Heparin-induced thrombocytopenia (HIT)Hypersensitivity reactionsOsteoporosis (long-term use)
06

Interacting drugs

Heparin (as both a molecule and an administered drug)

4 more in the full profile.

07

Biomarkers

Activated partial thromboplastin time (aPTT) for monitoring heparin efficacy

Beyond the preview

Go deeper on Glycosaminoglycan (heparin) (GAG (heparin)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycosaminoglycan (heparin) (GAG (heparin)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call